Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

James Michael Frederic Horgan has worked on the following 33 EPO patent applications which have been published in the last five years:

EP11833150

QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS

IPC classification:
A01N 43/54, C07D 239/42, C07D 401/04
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION IN PROGRESS
EP11766539

OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH

IPC classification:
A61K 31/42, A61K 31/535, A61P 19/02, C07D 263/46, C07D 413/04, C07D 413/14
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED
EP11836908

NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS

IPC classification:
A61K 31/40, A61K 31/445
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED
EP11775471

NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS

IPC classification:
A01N 43/38, A61K 31/405, A61P 1/10, C07D 401/14, C07D 403/14, C07D 417/14
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION IN PROGRESS
EP11772492

OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH

IPC classification:
A61K 31/13, A61K 31/42, A61K 31/435, C07D 413/14
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
The patent has been granted
EP11851281

QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS

IPC classification:
A61K 31/498, C07D 241/36
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
The patent has been granted
EP11836900

METHODS FOR IDENTIFYING NOTCH-SPARING GAMMA SECRETASE INHIBITORS

IPC classification:
C12Q 1/37
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION WITHDRAWN
EP11829799

GENERATION, CHARACTERIZATION AND USES THEREOF OF ANTI-HER3 ANTIBODIES

IPC classification:
A61K 39/395
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION WITHDRAWN
EP11810217

NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS

IPC classification:
A61K 31/40, A61P 13/00, C07D 401/14, C07D 417/14, C07D 487/04, C07D 491/107
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED
EP12768642

pAVEC

IPC classification:
C07H 21/04, C12N 15/11, C12N 15/64
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12782391

BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS

IPC classification:
A01N 43/40, A61K 31/44, C07D 213/04
Applicant:
Merck & Co. Inc.
Applicant:
Merck Canada Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION IN PROGRESS
EP12786546

THERAPEUTIC ANTI-IGF1R COMBINATIONS

IPC classification:
A61K 39/395, C07K 16/28, C12P 21/08
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION WITHDRAWN
EP11709969

USE OF PCSK9 AS A VACCINE FOR LOWERING CHOLESTEROL

IPC classification:
A61K 39/00, A61K 48/00, A61P 3/06, C12N 9/64
Applicant:
MSD Italia S.r.l.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION REFUSED
EP12746556

USE OF MDL-1 ANTAGONISTS TO TREAT SPONDYLARTHROPATHY

IPC classification:
A61K 38/00, A61K 38/17, A61K 39/395, A61P 19/02
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11833005

USES OF MACROPHAGE MANNOSE RECEPTOR TO SCREEN COMPOUNDS AND USES OF THESE COMPOUNDS

IPC classification:
A01N 25/00, A61K 38/14, A61K 47/48, C07K 1/00, C07K 14/00, C07K 17/00
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION REQUESTED
EP12760995

AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES

IPC classification:
A61K 31/4162, A61P 35/00, C07D 487/04
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION IN PROGRESS
EP12780029

AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

IPC classification:
A61K 31/427, A61K 31/44, A61P 11/00, A61P 11/06, A61P 19/02, A61P 35/00, C07D 401/02, C07D 417/14
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION IN PROGRESS
EP12782298

AMINOPYRIMIDINES AS SYK INHIBITORS

IPC classification:
A01N 43/54, A61K 31/505, A61K 31/506, A61P 11/06, A61P 35/00, C07D 417/12, C07D 417/14
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED
EP11775475

BIOMARKERS FOR IDIOPATHIC PULMONARY FIBROSIS

IPC classification:
C12Q 1/68
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12782164

PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS

IPC classification:
A61K 31/444, A61P 37/00, C07D 417/14
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED
EP12763896

STABLE FORMULATIONS OF ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 AND RELATED TREATMENTS

IPC classification:
A61K 9/19, A61K 39/00, A61K 39/395, C07K 16/28
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
EXAMINATION IN PROGRESS
EP12789452

METHOD FOR PREPARING Fc-CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES

IPC classification:
C07K 16/00, C07K 16/24, C07K 16/28, C07K 16/40, C07K 16/42, C12P 21/00
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck Sharp & Dohme Ltd.
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11775457

AZAINDOLES AS JANUS KINASE INHIBITORS

IPC classification:
A01N 43/42, A61K 31/44, C07D 471/04, C07D 519/00
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13180969

Beta-lactamase Inhibitors

IPC classification:
A61K 31/529, A61K 31/535, A61P 31/04, C07D 471/08, C07D 487/08, C07D 519/00
Applicant:
Merck Sharp & Dohme Corporation
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11778226

AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH

IPC classification:
A61K 31/437, A61P 19/02, A61P 25/00, A61P 29/00, C07D 471/04, C07D 519/00
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12181546

COMBINATIONS OF A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR WITH OTHER HCV AGENTS

IPC classification:
A61K 38/06, A61K 38/07, A61K 38/08, A61P 31/14, C07K 5/08, C07K 5/10, C07K 5/12
Applicant:
Merck Sharp & Dohme Corporation
Applicant:
MSD Italia S.r.l.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14838254

DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE, SUB-ACUTE OR CHRONIC COUGH

IPC classification:
A61K 31/505, C07D 239/28
Agent:
Anton Hutter, Venner Shipley LLP
Agent:
James Michael Frederic Horgan, Merck Sharp & Dohme Ltd.
Status:
GRANT OF PATENT INTENDED
EP12181533

PHARMACEUTICAL COMPOSITIONS COMPRISING A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR

IPC classification:
A61K 38/06, A61K 38/07, A61K 38/08, A61P 31/14, C07K 5/08, C07K 5/10, C07K 5/12
Applicant:
Merck Sharp & Dohme Corporation
Applicant:
MSD Italia S.r.l.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11772489

SUBSTITUTED PYRIMIDINES

IPC classification:
A61K 31/505, A61P 7/06, C07D 237/00
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED
EP11775473

MULTIWELL-PLATE REACTOR AND SYSTEM THEREFOR

IPC classification:
B01L 3/00, C12M 1/00, C12M 1/32, C12M 1/34, G01N 33/48
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
APPLICATION WITHDRAWN
EP11747972

METHOD FOR INCREASING N-GLYCOSYLATION SITE OCCUPANCY ON THERAPEUTIC GLYCOPROTEINS PRODUCED IN PICHIA PASTORIS

IPC classification:
C12N 1/00, C12N 15/74
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED
EP11850226

QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS

IPC classification:
A61K 31/4375, A61K 31/47, A61K 31/4709, A61K 31/496, A61P 11/00, C07D 215/48, C07D 401/06, C07D 401/12, C07D 401/14, C07D 405/12, C07D 471/04, C07D 491/107
Applicant:
Merck & Co. Inc.
Agent:
James Michael Frederic Horgan, Merck & Co. Inc.
Status:
PATENT GRANTED

Please Sign in to use this feature